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Abstract. The ISAC facility (Isotope Separation and Acceleration) at TRIUMF has recently started to provide
isotopes for pre-clinical nuclear medicine studies. By irradiating ISOL (Isotope Separation OnLine) targets with
a 480 MeV proton beam from the TRIUMF H- cyclotron, the facility can deliver a large variety of radioactive
isotope beams (RIB) for research in the fields of nuclear astrophysics, nuclear structure and material science
with half-lives down to a few milliseconds via an electrostatic beamline network. For the collection of medical
isotopes, typically with half-lives in the range of hours or days, we have developed a compact apparatus for
the implantation of mass-separated RIB on a target disc at energies between 20-55 keV. In this paper, we also
discuss two different retrieval methods of the implanted activity from the implantation target: by chemical
etching of the target surface and by recoil collection of implanted alpha emitters.
1 Introduction
The ISAC facility features two target stations for the irra-
diation of ISOL-type thick targets with up to 100 µA of
a 480 MeV proton beam from the TRIUMF H- cyclotron.
Using a variety of refractory target materials (metal foils,
composite ceramic carbides, oxides) a large number of ra-
dioactive isotope beams (RIB) can be produced by spal-
lation, fragmentation or fission from elements such as C,
Si, Ti, Ni, Nb, Ta, Th and U. Only sufficiently volatile
isotopes in atomic or molecular form for which the aver-
age release time doesn’t exceed their half-life too much
can be released, ionized, mass-separated and distributed
through the ISAC electrostatic beamline network. There-
fore, to accommodate a fast and efficient release, ISAC tar-
gets are generally operated at temperatures as high as per-
missible by the properties of the target material – mainly
vapor pressure, thermal conductivity, sintering behavior
and chemical stability. Operating temperatures range from
1100 °C for nickel oxide targets to 2300 °C for tantalum
metal foil targets [1]. The facility is mainly used for re-
search in the fields of nuclear astrophysics, nuclear struc-
ture and material science [2]. In addition to these appli-
cations, the facility is now also producing radioisotopes
for pre-clinical nuclear medicine research. Some of those
isotopes are of interest for imaging or therapeutic applica-
tions or both (theranostic isotopes). They generally have
half-lives in the range of hours or days and can be pro-
duced in sufficient quantities for pre-clinical research from
∗e-mail: pkunz@triumf.ca
a variety of target materials. The current status of verified
RIB yields is available for ISAC users in the ISAC Yield
Database [3].
This paper is providing an overview of of isotopes that
have already been collected as well as potential candi-
dates for future applications related to nuclear medicine
research. In particular, the collection of the heavy, al-
pha emitting isotope 225Ac and its precursor 225Ra are dis-
cussed. 225Ac [4] and its decay product 213Bi are promis-
ing candidates for targeted alpha therapy (TAT). Further-
more, methods to transfer the collected activity from the
implantation target have been investigated. Sample prepa-
ration methods such as chemical etching of implantation
targets and the recoil collection of 213Bi from the 225Ra/Ac
decay chain are discussed.
2 Experimental
The two target stations at the ISAC facility are operated
alternately. The 480 MeV proton beam can be directed at
either one of them where it impinges on a production tar-
get with a beam current of up to 100 µA with a maximum
achievable beam power of 48 kW. In order to accommo-
date the full capacity of the cyclotron, high-power tanta-
lum target containers [5] have been developed. The ad-
dition of cooling fins increases the emissivity to 92% and
allows to dissipate up to 25 kW of beam power. This is suf-
ficient since power deposition in the target material is usu-
ally less than 50% of the maximum beam power. Thick-
ness, density, thermal conductivity, vapor pressure are fac-
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Fig. 1. Section view of the ISAC Implantation chamber. The 
RIB is focused though a set of collimators on the implantation 
target in the back of the chamber.
tors that determine the maximum feasible beam power on 
target. The extraction of a beam from the ion source is only 
efficient under high-vacuum conditions (< 10−5 mbar) [6]. 
The vapor pressure depends strongly on the target tem-
perature which depends on power deposition and the effi-
ciency of power dissipation, governed by the thermal con-
ductivity of the target material and the emissivity of the 
target container. The resulting target temperature limita-
tions can be detrimental to the efficient and fast release 
of isotopes through diffusion and effusion which benefits 
from high operating temperatures. The best balance be-
tween these two opposing requirements can be achieved 
by using refractory materials with high thermal stability, 
low vapor pressure and good thermal conductivity. An-
other aspect considering target material properties are dif-
fusion times. Slow diffusion reduces the release efficiency 
of short-lived isotopes. This effect can be mitigated by 
using high-porosity materials. For example, the average 
bulk density of the uranium carbide used for ISAC targets 
is typically around 3.3 g/cm3 [7], about 1/3 of the theo-
retical density of UC2. In comparison to bulk UC2, the 
thermal conductivity of this porous material is reduced by 
a factor of 6. In order to still achieve sufficient power 
dissipation, composite ceramic target materials [8], con-
sisting of disks made of a 100-250 µm thick carbide layer 
on a 130 µm graphite backing foil have been developed. 
This configuration i ncreases t he overall t hermal conduc-
tivity significantly due to the relatively high conductivity 
of the graphite backing foils. For low-thermal conductiv-
ity oxide materials (NiO, UO2) 25 µm thick niobium metal 
backing foils serve as thermal conductivity booster.
The production rate for a specific isotope is the prod-
uct of production cross section, proton beam intensity and 
target thickness. The actual isotope beam intensity that 
arrives at the experiment also depends on the release ef-
ficiency form the t arget, the ionization efficiency and the
transport efficiency of the ion beam through the ISAC elec-
trostatic beamline network. Beam transport includes the
extraction and acceleration of ions from the ion source to
energies between 10-55 keV, subsequent mass separation
through a low resolution pre-separator, a high-resolution
mass separator (m/∆m=2000).
For the ionization process a variety of ion source op-
tions can be utilized [9]. Which ionization method is most
suitable, depends strongly on the ionization potential of
the atoms or molecules released from the target. The ion
beams discussed in this paper were ionized with a surface
ion source or by resonant laser ionization.
For the production of heavy isotopes for targeted al-
pha therapy research, composite ceramic uranium carbide
targets [7] are currently used. They have typical thick-
nesses between 0.05 and 0.1 mol U/cm2 and are irradiated
with a proton beam of max. 10 µA for up to 5000 µAh
(current operation license limits) at an operating tempera-
ture of approximately 1950 °C. Neutron-deficient isotopes
for medical applications in the lanthanide region are effi-
ciently produced from tantalum metal foil targets, which
are filled with several hundred 25 µm thick Ta foil disks
up to a total thickness of 0.14 mol/cm2. They are oper-
ated at up to 70 µA proton beam current and a target core
temperature of 2300°C [6].
2.1 ISAC Implantation Station (IIS)
The IIS is located a few meters behind the ISAC high-
resolution mass separator on a short branch of the electro-
static beamline. It is divided in two sections. Section 1
contains ion beam optics for beam positioning, focusing
or rastering. It ends at a gate valve with a pumping port
on it’s downstream side which provides vacuum for the
ion collection chamber (section 2). This chamber can be
custom-build for specific applications and is attached to
the gate valve by the user.
The design of the ion collection chamber used for the
examples presented in this paper is shown in figure 1. It is
made of a standard KF40 6-way cross. Attached are vent
and sampling valves to test for airborne contamination, a
vacuum gauge, a collimator with current readout for beam
centering and the implantation target mounted on an elec-
trical feedthrough to allow current monitoring during the
implantation process. In principle the target can have any
form and composition. The only condition is that it must
be electrically conductive to avoid charging and enable a
current readback. For the experiments in this paper we
used a standard aluminium SEM sample holder (25 mm)
with a machined-in 2 mm deep cut-out (16 mm), see fig-
ure 2. The cut-out is required for the etching process de-
scribed in 2.2. A manual KF40 gate valve serves as an
interface to section 1. Once an implantation is finished the
gate valves in both sections are closed and the volume be-
tween them is vented. Now, the ion collection chamber
can be detached and - still under vacuum - be transferred
to the radiochemistry laboratory. This way, the collected
activity can be considered a closed source, which is im-
portant particularly for alpha emitters where the spread of
contamination through recoil emission can be a problem.
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Fig. 2. 225Ac recoil collection depends on the stopping range of approx. 100 keV alpha decay recoils (left) and the bias between the 
implantation target (insert, dimensions in mm) and an identical ion catcher target. The measured 213Bi collection efficiency (right) at 
normal air pressure for a configuration in which the catcher target was pressed against the implantation target, separated by a thin 
insulator. A negative bias was applied to the catcher.
Once in the lab, the chamber can be vented and the im-
plantation target can be retrieved for further processing.
2.2 Retrieval of activity from IIS targets
We have explored 2 methods to retrieve radioactive iso-
topes from the implantation target: chemical etching of the
target surface (2.2.1) and recoil collection from implanted
alpha emitters (2.2.2)
2.2.1 Chemical etching
The implantation depth of a heavy 225Ac/Ra ion beam at a
typical ISAC extraction energy of 30 keV in aluminium is
about 20 nm [10]. Therefore, the transfer of the implanted
isotopes into an aqueous solution requires the removal of
at least 20 nm of the implantation target surface.
To achieve this, 0.1 ml of 0.1N HCl is filled into the
implantation target cut-out and then gently evaporated on
a hot plate. Then the target is cooled down and a thin layer
of AlCl3, that has formed during the evaporation, is dis-
solved with 0.1 ml 0.1N HCl. This solution is picked up
with a micropipette and transferred to a vial. This etch-
rinse procedure is repeated several times. 3 iterations al-
ready remove >95% of the implanted activity, leaving it in
a small volume of acidic solution which can be used for
further radiochemical experiments.
2.2.2 Recoil collection
Isotopes like 223−225Ra and 225Ac decay through relatively
long chains, including multiple alpha decays. The recoil
energy transferred during an alpha decay to the residual
nucleus is around 100 keV, about 3 times larger than the
typical ion beam implantation energy at ISAC. Therefore,
the alpha decay recoils have sufficient kinetic energy to
escape as long as the recoil vector points out of the target.
For a thick implantation target, as was used in these exper-
iments, this leads to a theoretical release efficiency of less
than 50 % for a single alpha decay. However, the collec-
tion of 213Bi from a 225Ac source involves 3 alpha decays
in the chain. The decays of 221Fr and 217At contribute to
the overall release efficiency, increasing it to 60% at an
implantation energy of 30 keV. This result was confirmed
with a GEANT4 [11] recoil track simulation.
Using a 225Ac/Ra target as shown in figure 2, 213Bi re-
coils were accumulated by placing an identical collection
target, separated by a thin insulator, directly on top. The
collection was ended when the activity of 213Bi (T1/2 =
45.59 min) had reached saturation. Figure 2 (right) shows
that a negative bias of >20 V lead to a collection efficiency
for 213Bi of ∼35 %.
The stopping range of recoils in air under normal pres-
sure is less than 0.1 mm, see figure 2 (left). Aligning
the stopping range more accurately with the distance be-
tween source and collector by reducing the pressure to 50
mbar and using argon as a buffer gas increased the col-
lection efficiency to 47%. However, for applications such
as chelation studies a 35% efficiency was sufficient and
sample collection under normal air pressure much more
convenient.
3 Conclusion
All measured yield rates from ISAC targets are compiled
in Ref. [3]. From these values, activities can be ex-
trapolated either until saturation is reached or to a maxi-
mum 24 hour implantation period. This is a realistic time
frame, considering that radioactive ion beam time is usu-
ally allocated for several experiments with one ISAC tar-
get. Within this period, a 225Ac beam (T1/2 = 9.92 d) at a
rate of 1.3 ·108 ions/s from a uranium carbide target / laser
3
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Table 1. Selected isotopes for potential medical applications from ISAC targets. The table lists primary collection beam, target
material, ion source and established yields [3] and the activity that can be accumulated within a typical 24h beam collection period.
Isotope Half-life Application Primary Target Ion Measured yield Accumulated
beam material source [ions/s] 24h Activity [Bq]
225Ac 9.92 d TATa 225Ac UC LIS f f 1.30E+08 8.60E+06
225Ac 9.92 d TATa 225Ra UC SISgg 1.70E+08 3.40E+06
224Ra 3.66 d TATa 224Ra UC SISg 1.60E+09 2.70E+08
223Ra 11.43 d TATa 223Ra ThO SISg 6.90E+08 4.00E+07
213Bi 45.6 m TATa 225Ac UC SISg 6.70E+07 2.25E+06
212Pb 10.64 h TATa 224Ra UC SISg 1.60E+09 1.00E+08
212Bi 60.6 m TATa 224Ra UC SISg 1.60E+09 7.80E+07
211At 7.22 h TATa 211Rn UO FEBIADh 1.00E+08 2.40E+07
211At 7.22 h TATa 211At UO FEBIADh 8.40E+07 7.40E+07
211At 7.22 h TATa 211Fr UC SISg 1.90E+09 4.30E+07
209At 5.4 h SPECTb 213Fr UC SISg 1.80E+09 8.50E+08
209At 5.4 h SPECTb 209At ThO LIS f 1.90E+08 1.70E+08
177Lu 6.65 d BTc 177Lu Ta LIS f 6.50E+08 6.40E+07
169Yb 32.02 d SPECTb 169Yb Ta LIS f 5.10E+10 1.00E+09
166Yb 2.36 d ATd 166Yb Ta LIS f 1.50E+11 3.70E+10
165Er 10.3 h ATd 165Yb/165Tm Ta LIS f 9.32E+10 3.90E+10
161Ho 2.5 h ATd 161Ho Ta LIS f 9.96E+09 9.30E+09
161Ho 2.5 h ATd 161Er Ta LIS f 1.03E+10 3.90E+09
149Tb 4.12 h TATa/SPECTb 149Tb Ta SISg 5.78E+08 5.75E+08
140Nd 3.37 d PETe/ATc 140Sm Ta LIS f 9.70E+08 1.70E+08
124I 4.18 d PETe 124I UO FEBIADh 2.20E+08 3.20E+07
123I 13.22 h PETe 123I UO FEBIADh 3.80E+07 2.60E+07
82Sr 1.35 d PETe 82Sr Nb SISg 1.00E+10 2.10E+08
77Br 57.0 h Labeling 77Rb Nb SISg 1.60E+09 3.70E+08
67Ga 78.28 h Imaging 67Ga ZrC LIS f 8.10E+09 1.50E+09
67Cu 2.58 d BTc 67Cu Ta LIS f 1.40E+08 3.10E+07
64Cu 12.70 h PETe/therapy 64Cu Nb LIS f 3.20E+09 2.20E+09
61Cu 3.33 h PETe 61Cu Nb LIS f 7.80E+08 7.50E+08
a targeted alpha therapy, b single-photon emission computed tomography, c beta therapy, d Auger therapy, e positron emission
tomography, f laser ion source, , g surface ion source , h forced electron beam induced arc discharge ion source
ion source combination accumulates an activity of up to
8.6 · 106 Bq. The accompanying 225Ra (T1/2 = 14.8 d)
beam is collected simultaneously. At a rate of 1.7 · 108
ions/s from a uranium carbide target / surface ion source
combination a total of 1.4 · 1013 atoms (7.5 · 106 Bq) can
be collected in 24 hours. 225Ra decays via β-decay into
225Ac, reaching a maximum activity of 3.4 · 106 Bq 225Ac
approximately 18 days after the implantation.
The etching method (section 2.2.1) was used to extract
Ac and Ra isotopes. Then the radium was separated from
the actinium by well established extraction chromatogra-
phy methods [12]. The remaining 225Ra can be recycled
and used as an 225Ac generator. This has been demon-
strated as part of the development of Multi-isotope SPECT
imaging of the 225Ac decay chain by Robertson et. al. [13].
The collection of 213Bi via recoil transfer was employed
during chelation studies. In this case the collected activ-
ities were significantly lower, in the kBq range, but still
sufficient for this kind of experiment. The recoil transfer
from the low energy beta decay of 225Ra is insignificant
compared to the implantation energy and, therefore, stays
in the implantation target, while it’s decay product 225Ac
can escape, thus, extending the lifetime of the 213Bi source
significantly.
With the example of 225Ac/Ra beams, it has been
demonstrated that the ISAC facility at TRIUMF has the ca-
pability of providing pure isotope samples for pre-clinical
nuclear medicine research [14]. Infrastructure for the
ISAC Implantation Station and methods for production
and retrieval of medical isotopes have been established.
Similar implantation procedures have also been applied
to the production of 209/211At via the implantation of
211/213Fr beams for At-based α-therapy research [15][16].
In principle, the methods described above are applicable
for any isotope beam from ISAC targets.
Table 1 lists the established yield rates (Ref. [3]) of
isotopes of potential interest for nuclear medicine research
from various targets and ion sources. Based on the es-
tablished yields, the activity accumulated over a 24h im-
plantation period was extrapolated. The data shows that
in particular for some lanthanides very high activities can
be collected. However, for relatively long-lived isotopes,
such as 225Ra and 225Ac larger activities could be obtained
by simply increasing the implantation period.
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ions/s from a uranium carbide target / surface ion source
combination a total of 1.4 · 1013 atoms (7.5 · 106 Bq) can
be collected in 24 hours. 225Ra decays via β-decay into
225Ac, reaching a maximum activity of 3.4 · 106 Bq 225Ac
approximately 18 days after the implantation.
The etching method (section 2.2.1) was used to extract
Ac and Ra isotopes. Then the radium was separated from
the actinium by well established extraction chromatogra-
phy methods [12]. The remaining 225Ra can be recycled
and used as an 225Ac generator. This has been demon-
strated as part of the development of Multi-isotope SPECT
imaging of the 225Ac decay chain by Robertson et. al. [13].
The collection of 213Bi via recoil transfer was employed
during chelation studies. In this case the collected activ-
ities were significantly lower, in the kBq range, but still
sufficient for this kind of experiment. The recoil transfer
from the low energy beta decay of 225Ra is insignificant
compared to the implantation energy and, therefore, stays
in the implantation target, while it’s decay product 225Ac
can escape, thus, extending the lifetime of the 213Bi source
significantly.
With the example of 225Ac/Ra beams, it has been
demonstrated that the ISAC facility at TRIUMF has the ca-
pability of providing pure isotope samples for pre-clinical
nuclear medicine research [14]. Infrastructure for the
ISAC Implantation Station and methods for production
and retrieval of medical isotopes have been established.
Similar implantation procedures have also been applied
to the production of 209/211At via the implantation of
211/213Fr beams for At-based α-therapy research [15][16].
In principle, the methods described above are applicable
for any isotope beam from ISAC targets.
Table 1 lists the established yield rates (Ref. [3]) of
isotopes of potential interest for nuclear medicine research
from various targets and ion sources. Based on the es-
tablished yields, the activity accumulated over a 24h im-
plantation period was extrapolated. The data shows that
in particular for some lanthanides very high activities can
be collected. However, for relatively long-lived isotopes,
such as 225Ra and 225Ac larger activities could be obtained
by simply increasing the implantation period.
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